Acurx Pharmaceuticals (ACXP)
NASDAQ:ACXP
Want to see ACXP full AI Analyst Report?
Total Valuation
Acurx Pharmaceuticals has a market cap or net worth of $8.12M. The enterprise value is -$6.26M.
Market Cap$8.12M
Enterprise Value-$6.26M
Share Statistics
Acurx Pharmaceuticals has 4,297,738 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,297,738
Owned by Insiders55.41%
Owned by Institutions0.34%
Financial Efficiency
Acurx Pharmaceuticals’s return on equity (ROE) is -1.51 and return on invested capital (ROIC) is -153.59%.
Return on Equity (ROE)-1.51
Return on Assets (ROA)-1.04
Return on Invested Capital (ROIC)-153.59%
Return on Capital Employed (ROCE)-1.54
Revenue Per Employee0.00
Profits Per Employee-1.99B
Employee Count4
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Acurx Pharmaceuticals is ―. Acurx Pharmaceuticals’s PEG ratio is 0.00672.
PE Ratio―
PS Ratio0.00
PB Ratio0.71
Price to Fair Value0.71
Price to FCF>-0.01
Price to Operating Cash Flow-0.46
PEG Ratio0.00672
Income Statement
In the last 12 months, Acurx Pharmaceuticals had revenue of 0.00 and earned -7.97M in profits. Earnings per share was -5.32.
Revenue0.00
Gross Profit0.00
Operating Income-8.09M
Pretax Income-7.97M
Net Income-7.97M
EBITDA-8.09M
Earnings Per Share (EPS)-5.32
Cash Flow
In the last 12 months, operating cash flow was -6.14M and capital expenditures 3.00, giving a free cash flow of -6.14M billion.
Operating Cash Flow-6.14M
Free Cash Flow-6.14M
Free Cash Flow per Share-1.43
Dividends & Yields
Acurx Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.43
52-Week Price Change-76.26%
50-Day Moving Average3.07
200-Day Moving Average3.71
Relative Strength Index (RSI)38.79
Average Volume (3m)1.14M
Important Dates
Acurx Pharmaceuticals upcoming earnings date is Aug 17, 2026, After Close (Confirmed).
Last Earnings DateMay 12, 2026
Next Earnings DateAug 17, 2026
Ex-Dividend Date―
Financial Position
Acurx Pharmaceuticals as a current ratio of 3.18, with Debt / Equity ratio of 0.00%
Current Ratio3.18
Quick Ratio3.18
Debt to Market Cap0.00
Net Debt to EBITDA933.78
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Acurx Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Acurx Pharmaceuticals EV to EBITDA ratio is 933.31, with an EV/FCF ratio of 1.11.
EV to Sales0.00
EV to EBITDA933.31
EV to Free Cash Flow1.11
EV to Operating Cash Flow1.11
Balance Sheet
Acurx Pharmaceuticals has $9.25M in cash and marketable securities with $0.00 in debt, giving a net cash position of $9.25M billion.
Cash & Marketable Securities$9.25M
Total Debt$0.00
Net Cash$9.25M
Net Cash Per Share$2.15
Tangible Book Value Per Share$3.51
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Acurx Pharmaceuticals is $17.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$17.00
Price Target Upside511.51% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast68.70%